Injectable semaglutide formulations, GLP-1 receptor agonists, used in type 2 diabetes and obesity management. Pharmaceutical producers distribute to specialty pharmacies, hospitals, and clinics. Sourced by diabetologists and procurement staff for administration in outpatient endocrinology practices and patient self-use.